InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List

BEIJING, Dec. 2, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL) by theA China National Healthcare Security AdministrationA (NHSA). Orelabrutinib is an oral, once-daily BTK inhibitor with national Category 1 designation. It is included in the NDRL as the treatment of patients with r/r Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL), and the treatment of patients with r/r Mantle Cell Lymphoma (MCL)."Lymphoma is one of the malignant tumors with the fastest growth of incidence rate and one of the top ten malignant tumors with the highest mortality rate in China. The inclusion of orelabrutinib in the NRDL could significantly improve access of this innovative drug in China, which can benefit more patients," said Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare."We are grateful that orelabrutinib has been included in the NRDL. We will continue to fulfil our mission -- 'Science drives innovation for the benefit of patients', and accelerate exploring more indications for orelabrutinib," said Dr. Cui.A Orelabrutinib has excellent target selectivity with near 100% BTK occupancy. Orelabrutinib's once-daily oral administration is convenient for continued treatment.About Orelabrutinib
Orelabrutinib is a small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and autoimmune diseases.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2022    »